Alexander Burges1, Barbara Schmalfeldt. 1. Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe-Großhadern. Alexander.Burges@med.uni-muenchen.de
Abstract
BACKGROUND: Patients with ovarian cancer usually present to a family physician with nonspecific symptoms, most often abdominal pain. The outcome depends above all on the stage of the disease when it is diagnosed and on the quality of treatment. METHODS: This article is based on a review of selected publications from 2000 to 2010 that were retrieved by an automated search in Medline on the terms "ovarian cancer," "screening," "diagnosis," "treatment," and "prognosis," as well as the interdisciplinary S2k guideline Diagnostik und Therapie maligner Ovarialtumoren (the diagnosis and treatment of malignant ovarian tumors) issued in 2007 by the Ovarian Tumor Committee of the German Consortium of Gynecologic Oncology (AGO) and the Committee's updated recommendations of 2009. RESULTS: The proper treatment of early ovarian cancer involves resection of the primary tumor and all macroscopically visible tumor mass as well as meticulous inspection of the entire abdominal cavity for staging. Platinum-based chemotherapy is indicated for women with ovarian cancer in FIGO stage I to IIA (except stage IA, G1). For women with advanced ovarian cancer, the prognosis largely depends on the extent of tumor mass reduction on initial surgery. Complete resection confers significantly longer survival (median 5 years) than incomplete resection. After surgery, the standard adjuvant chemotherapy consists of a combination of carboplatin and paclitaxel. Treatment that conforms to published guidelines significantly improves survival (60% versus 25% at 3 years). CONCLUSION: The possibility of ovarian cancer must be considered for any woman who presents with new, persistent, nonspecific abdominal pain. Ovarian cancer should always be treated in accordance with published guidelines.
BACKGROUND:Patients with ovarian cancer usually present to a family physician with nonspecific symptoms, most often abdominal pain. The outcome depends above all on the stage of the disease when it is diagnosed and on the quality of treatment. METHODS: This article is based on a review of selected publications from 2000 to 2010 that were retrieved by an automated search in Medline on the terms "ovarian cancer," "screening," "diagnosis," "treatment," and "prognosis," as well as the interdisciplinary S2k guideline Diagnostik und Therapie maligner Ovarialtumoren (the diagnosis and treatment of malignant ovarian tumors) issued in 2007 by the Ovarian Tumor Committee of the German Consortium of Gynecologic Oncology (AGO) and the Committee's updated recommendations of 2009. RESULTS: The proper treatment of early ovarian cancer involves resection of the primary tumor and all macroscopically visible tumor mass as well as meticulous inspection of the entire abdominal cavity for staging. Platinum-based chemotherapy is indicated for women with ovarian cancer in FIGO stage I to IIA (except stage IA, G1). For women with advanced ovarian cancer, the prognosis largely depends on the extent of tumor mass reduction on initial surgery. Complete resection confers significantly longer survival (median 5 years) than incomplete resection. After surgery, the standard adjuvant chemotherapy consists of a combination of carboplatin and paclitaxel. Treatment that conforms to published guidelines significantly improves survival (60% versus 25% at 3 years). CONCLUSION: The possibility of ovarian cancer must be considered for any woman who presents with new, persistent, nonspecific abdominal pain. Ovarian cancer should always be treated in accordance with published guidelines.
Authors: A P M Heintz; F Odicino; P Maisonneuve; M A Quinn; J L Benedet; W T Creasman; H Y S Ngan; S Pecorelli; U Beller Journal: Int J Gynaecol Obstet Date: 2006-11 Impact factor: 3.561
Authors: Eric L Eisenhauer; Nadeem R Abu-Rustum; Yukio Sonoda; Douglas A Levine; Elizabeth A Poynor; Carol Aghajanian; William R Jarnagin; Ronald P DeMatteo; Michael I D'Angelica; Richard R Barakat; Dennis S Chi Journal: Gynecol Oncol Date: 2006-08-04 Impact factor: 5.482
Authors: Murray Joseph Casey; Carrie Synder; Chhanda Bewtra; Steven A Narod; Patrice Watson; Henry T Lynch Journal: Gynecol Oncol Date: 2005-05 Impact factor: 5.482
Authors: R I Olivier; M van Beurden; M A C Lubsen; M A Rookus; T M Mooij; M J van de Vijver; L J van't Veer Journal: Br J Cancer Date: 2004-04-19 Impact factor: 7.640
Authors: Sarah R Irvin; Elisabete Weiderpass; Frank Z Stanczyk; Louise A Brinton; Britton Trabert; Hilde Langseth; Nicolas Wentzensen Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-01-13 Impact factor: 4.254
Authors: Marcin Michalak; Michał S Lach; Sylwia Borska; Błażej Nowakowski; Kazuo Umezawa; Wiktoria M Suchorska Journal: Am J Cancer Res Date: 2021-12-15 Impact factor: 6.166
Authors: Margo Steuperaert; Giuseppe Falvo D'Urso Labate; Charlotte Debbaut; Olivier De Wever; Christian Vanhove; Wim Ceelen; Patrick Segers Journal: Drug Deliv Date: 2017-11 Impact factor: 6.419
Authors: Elisabeth Smolle; Valentin Taucher; Martin Pichler; Edgar Petru; Sigurd Lax; Johannes Haybaeck Journal: Int J Mol Sci Date: 2013-05-02 Impact factor: 5.923